Clinical trial
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With…
NCT00385385 · ActivBiotics, Industry · Unknown status
Key facts
| NCT number | NCT00385385 |
|---|---|
| Title | RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease |
| Official title | Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid Atherosclerosis and Intima Media Thickness |
| Lead sponsor | ActivBiotics, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | Rifalazil |
| Enrollment | 72 |
| Start date | Oct 1, 2006 |
| Completion | Sep 1, 2008 |
| First posted | Oct 9, 2006 |
| Last update posted | Apr 30, 2007 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: